Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity

Hendricks, Audrey E.; Bochukova, Elena G.; Marenne, Gaëlle; Keogh, Julia M.; Atanassova, Neli; Bounds, Rebecca; Wheeler, Eleanor; Mistry, Vanisha; Henning, Elana; Körner, Antje; Muddyman, Dawn; McCarthy, Shane; Hinney, Anke; Hebebrand, Johannes; Scott, Robert A.; Langenberg, Claudia; Wareham, Nick J.; Surendran, Praveen; Howson, Joanna M.; Butterworth, Adam S.; Danesh, John; Nordestgaard, Børge G; Nielsen, Sune F; Afzal, Shoaib; Papadia, Sofia; Ashford, Sofie; Garg, Sumedha; Millhauser, Glenn L.; Palomino, Rafael I.; Kwasniewska, Alexandra; Tachmazidou, Ioanna; O’Rahilly, Stephen; Zeggini, Eleftheria; Barroso, Inês; Farooqi, I. Sadaf

doi:10.1038/s41598-017-03054-8

Download PDF

Article
Open access
Published: 29 June 2017

Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity

Audrey E. Hendricks^1,2^na1,
Elena G. Bochukova^3,4^na1,
Gaëlle Marenne¹,
Julia M. Keogh³,
Neli Atanassova³,
Rebecca Bounds³,
Eleanor Wheeler¹,
Vanisha Mistry³,
Elana Henning³,
Antje Körner^5,6,
Dawn Muddyman¹,
Shane McCarthy¹,
Anke Hinney⁷,
Johannes Hebebrand⁷,
Robert A. Scott⁸,
Claudia Langenberg⁸,
Nick J. Wareham⁸,
Praveen Surendran⁹,
Joanna M. Howson⁹,
Adam S. Butterworth^9,10,
John Danesh^1,9,10,
Børge G Nordestgaard^11,12,
Sune F Nielsen^11,12,
Shoaib Afzal^11,12,
Sofia Papadia³,
Sofie Ashford³,
Sumedha Garg³,
Glenn L. Millhauser¹³,
Rafael I. Palomino¹³,
Alexandra Kwasniewska³,
Ioanna Tachmazidou¹,
Stephen O’Rahilly³,
Eleftheria Zeggini¹,
Inês Barroso^1,3,
I. Sadaf Farooqi³,
Understanding Society Scientific Group,
EPIC-CVD Consortium &
UK10K Consortium

Scientific Reports volume 7, Article number: 4394 (2017) Cite this article

5111 Accesses
45 Citations
12 Altmetric
Metrics details

Subjects

Abstract

Obesity is a genetically heterogeneous disorder. Using targeted and whole-exome sequencing, we studied 32 human and 87 rodent obesity genes in 2,548 severely obese children and 1,117 controls. We identified 52 variants contributing to obesity in 2% of cases including multiple novel variants in GNAS, which were sometimes found with accelerated growth rather than short stature as described previously. Nominally significant associations were found for rare functional variants in BBS1, BBS9, GNAS, MKKS, CLOCK and ANGPTL6. The p.S284X variant in ANGPTL6 drives the association signal (rs201622589, MAF~0.1%, odds ratio = 10.13, p-value = 0.042) and results in complete loss of secretion in cells. Further analysis including additional case-control studies and population controls (N = 260,642) did not support association of this variant with obesity (odds ratio = 2.34, p-value = 2.59 × 10⁻³), highlighting the challenges of testing rare variant associations and the need for very large sample sizes. Further validation in cohorts with severe obesity and engineering the variants in model organisms will be needed to explore whether human variants in ANGPTL6 and other genes that lead to obesity when deleted in mice, do contribute to obesity. Such studies may yield druggable targets for weight loss therapies.

Protein-truncating variants in BSN are associated with severe adult-onset obesity, type 2 diabetes and fatty liver disease

Article Open access 04 April 2024

Yajie Zhao, Maria Chukanova, … John R. B. Perry

Evaluation of the MC4R gene across eMERGE network identifies many unreported obesity-associated variants

Article Open access 20 September 2020

Bahram Namjou, Ian B. Stanaway, … John B. Harley

Loss-of-function mutations in MRAP2 are pathogenic in hyperphagic obesity with hyperglycemia and hypertension

Article 07 November 2019

Morgane Baron, Julie Maillet, … Amélie Bonnefond

Introduction

Studies focused on severe early onset obesity alone, or obesity with developmental delay and/or dysmorphic features have identified a number of genes harbouring highly penetrant causal mutations^{1, 2}. The further characterisation of rare, highly penetrant variants identified in such individuals can provide insights into the cellular and physiological mechanisms involved in energy homeostasis and human obesity, and can identify and/or validate targets for therapeutic intervention. The aim of our study was to examine the prevalence of rare/novel variants in human and mouse obesity genes using high-throughput next-generation sequencing in a large cohort of individuals with severe early onset obesity. Here we describe results from an analysis of 119 candidate genes sequenced in 2,548 individuals with severe, early-onset obesity from the Severe Childhood Onset Obesity Project (SCOOP)³ (UK individuals of European ancestry recruited to the Genetics of Obesity Study, GOOS; BMI standard deviation score (SDS) > 3; onset of obesity before the age of 10 years; Methods) from the UK10K project⁴. Our analysis includes 737 SCOOP individuals with whole-exome sequence, and 1,811 additional SCOOP individuals, not consented for whole-exome analysis, in whom we performed targeted sequencing. As this work was performed as part of a consortium (UK10K project), this data was compared to 1,117 individuals with other disorders (e.g. neurodevelopmental and rare disease) in whom exome sequencing and analysis were performed using the same methods. For the purposes of this analysis, these individuals are designated as “controls” (Methods), although we recognise that there are limitations with this design.

Study Design

SCOOP individuals likely to have congenital leptin deficiency, a treatable cause of severe obesity, were excluded by measurement of serum leptin, and individuals with mutations in the melanocortin 4 receptor gene (MC4R) (the most common genetic form of penetrant obesity) were excluded by prior Sanger sequencing.

We focused on six tiers of genes (Methods and Supplementary Table 1): (1) genes known to harbour variants causing human obesity alone (Obesity Alone; n = 6); (2) genes in which known variants cause human obesity combined with developmental delay and/or dysmorphology (Obesity and Delay; n = 26); (3) genes in which loss-of-function leads to obesity in mice (LoF Mice; n = 51); (4) genes in which gain-of-function leads to obesity in mice (GoF Mice, n = 5); (5) genes encoding anorectic peptides and their receptors (Anorectic Molecules, n = 7), and (6) genes in which loss-of-function is associated with other metabolic phenotypes in mice (Complex Metabolic Effects, n = 24). Our aim was to include genes where there was sufficient evidence to indicate disorders with Mendelian inheritance (obesity syndromes) or where complete deletion or overexpression (as opposed to conditional knockouts) causes an obesity phenotype in mice (Methods) (i.e. genes in which inherited loss/gain of function variants might exist). To identify variants more likely to be causally linked to obesity, we focused on rare (MAF < 1%) and novel (not seen in the data we used for filtering) variants predicted to be functional (i.e. nonsense variants, missense amino acid substitutions, alterations of conserved splice sites or small insertions/deletions (indels) that introduced a frameshift) (Methods). We filtered our data against approximately 8,000 publicly available sequenced samples, as well as 2,097 exomes (sequenced in parallel on the same platform as our samples) and 3,781 whole-genome sequenced samples also from the UK10K project (Methods).

Human Obesity Syndrome Genes

Firstly, we sought to identify rare and novel functional variants in the 32 genes known to cause human obesity, with or without, additional developmental delay and/or dysmorphology features (Obesity Alone, or Obesity and Delay) (Methods). We identified 11 rare potentially functional variants in ClinVar with pathogenic/likely pathogenic status and 321 novel functional variants, which we confirmed by Sanger sequencing (Fig. 1, Methods). Based on inheritance patterns (where available) and the functional properties of variants that have previously been characterised, variants in these genes may contribute to obesity, sometimes in a non-fully penetrant manner, in 52 (2%) individuals (Supplementary Figure 1 & Supplementary Table 2; Fig. 2, Methods). As variants in MC4R account for approximately 5% of severe obesity in this cohort⁵, these findings indicate that > 90% of patients within this cohort do not have their phenotype explained by variants in known human obesity genes. Further analysis exploring the whole-exome in an agnostic manner, with appropriately matched non-disease controls not available in the UK10K project, will be an aim of future investigations.

Notably, we identified thirteen clinically associated GNAS variants in fourteen SCOOP individuals (12 of these confirmed on Sanger sequencing; 0.5%) (Supplementary Table 3). GNAS is an imprinted gene in which heterozygous loss-of-function variants are associated with obesity, short stature and skeletal abnormalities, and, when maternally inherited, hormone resistance syndromes⁶. As GNAS sequencing has traditionally only been performed in individuals with classical clinical features, our findings suggest that the true prevalence in childhood obesity may be underappreciated. Three of the variants found in our study have been described previously in patients with classical features (p.Y163X⁷; p.R258W⁸, and p.R265H⁹). We identified a novel nonsense variant (p.Y169X) predicted to remove the entire Ras-like GTPase domain and several missense variants predicted to affect downstream signalling by affecting the interaction with G-protein coupled receptors (GPCRs), G-protein β- and γ-subunits, or downstream adenylyl cyclase when mapped onto the protein structure of GNAS (Fig. 3). We confirmed maternal transmission of variants in three out of the five families where parental samples were available for genotyping. Although four GNAS variant carriers exhibited endocrinopathies and nine had developmental delay as anticipated, unexpectedly four individuals had accelerated linear growth in childhood (height SDS > 2) rather than short stature (defined as height sds < 2.0) (Supplementary Table 3). Further molecular and physiological studies will be needed to investigate potential genotype-phenotype correlations. As studies in rodents have shown that Gnas is imprinted in the paraventricular nucleus of the hypothalamus¹⁰, the location of the majority of neurons expressing the G-protein coupled receptor MC4R, it is plausible to hypothesize that some GNAS variants may contribute to obesity and accelerated linear growth by reducing melanocortin signalling.

Next we formally tested for enrichment of rare, or novel, functional variants in case-control analysis¹¹ (Methods). Although no gene attained experiment-wide threshold of p-value < 2 × 10⁻⁴ (Methods and Supplementary Tables 4–9), four genes (BBS1, BBS9, GNAS, and MKKS) known to cause obesity and developmental delay and/or dysmorphology (Obesity and Delay) had nominally significant burden test p-values (p-value < 0.05) and a higher burden of variants in cases than controls (Table 1).

Table 1 Summary of case-control results.

Full size table

Mouse Obesity Genes

We found a higher burden of rare variants in cases than controls for two genes known to cause obesity when disrupted in mice - ANGPTL6 and CLOCK (Table 1). Testing the functional consequences of CLOCK variants in cells is not straightforward as the molecular mechanisms that lead to obesity are not fully understood. As such, we focused on verifying the accuracy of the computationally predicted function of all twelve rare ANGPTL6 variants (Methods, Fig. 4, Supplementary Table 10). All variants found in cases (but not the one variant found exclusively in controls, V143L) were predicted to affect the fibrinogen-like domain of the protein (Fig. 4a). ANGPTL6 is predominantly expressed in the liver but is also expressed in white adipose tissue and kidney. To evaluate the effect of these variants, HEK293 cells were transiently transfected with constructs encoding wild type and variant forms of ANGPTL6. Whereas wild-type ANGPTL6 was readily detected in the medium, several mutants reduced, and the S286X mutant abolished, secretion of ANGPTL6 (Fig. 4b). Incorporation of this functional information did not qualitatively change the results of the ANGPTL6 gene-based test (Supplementary Table 10). However, limiting the analysis to the single variant that completely abolished protein secretion (p.S286X, rs201622589) led to an adjusted OR = 10.13 and p-value = 0.028 (Fisher’s p-value = 0.041) suggesting that the association signal at this gene is primarily driven by this variant (Supplementary Table 10). To increase power, and given that there were no additional cases of European descent from our obesity cohort, we analysed existing exome-chip data from an additional 253,587 unrelated European, non-Finnish population controls (Methods, Supplementary Table 11). In an updated analysis with the 2,548 cases and 253,587 controls, we observed an odds ratio (OR) = 2.90 and a Fisher’s p-value = 0.0022, which did not reach experiment or exome-wide significance. Further analysis of 1,436 non-overlapping obesity cases and 1,954 non-overlapping controls from two studies did not lend additional support, and when combined with the original data, yielded an overall OR = 2.34 and chi-squared p-value = 0.0060 (total 3,984 cases vs 256,658 controls, Supplementary Table 11). The results are similar when limiting to non-obese controls (Supplementary Table 12). These findings highlight the difficulty in studying very rare variants in complex diseases, and potentially the effect of winner’s curse, reinforcing the need for extremely large sample sizes¹². Of interest, mice with targeted deletion of Angptl6 that survive to birth (20%) develop marked obesity, have increased food intake, reduced energy expenditure, exhibit lipid accumulation in liver and muscle, and develop insulin resistance¹³. Conversely, mice with targeted overexpression of Angptl6 are lean, insulin sensitive and are protected from diet-induced obesity¹³. As ANGPTL6 is a liver-derived circulating peptide, and thus could potentially be manipulated for therapeutic purposes¹⁴, further genetic studies in larger cohorts and experimental studies in mice and humans are necessary to explore its role in obesity and potential utility as an anti-obesity drug target.

Power and Gene Set Analysis

Assuming an experiment-wide significance level of 2 × 10⁻⁴ and that 30% of rare (MAF < 1%) variants within a given gene are causal we have very limited power (~20%) to detect an association to a gene region using our sample of 2,548 cases and 1,117 controls (Supplementary Figure 2, Online Methods, Supplementary Note 4)¹². As there is evidence that looking across group of genes with stronger priors may increase power^15,16,17, we tested for association of rare or novel functional variants within each of the six candidate gene sets. We further filtered variants with respect to their likelihood of being deleterious and performed six nested tests for each gene set (Methods). Although none of the analyses of tiered gene sets reached experiment-wide significance (Supplementary Table 13, Fig. 5), we see an increase in OR as we focus on rarer variants with more evidence of predicted deleterious effect within the Obesity Alone gene set. This suggests that focusing on extremely rare variants with strong evidence of being deleterious may be a good strategy for diseases with a complex genetic architecture, which likely includes rare, highly penetrant alleles. Our power analyses also suggests that restricting the MAF threshold to be near the very rare allele frequency of that expected for the causal variants, rather than a more lenient MAF threshold of 1%, increases power (Supplementary Figure 3). Finally, there are nominally significant signals (p-value < 0.05) within the LoF Mice candidate gene set for the novel, functional variant tests suggesting that within this rather large gene set (n = 51) there may be additional genes associated with human early onset obesity (Fig. 5).

Discussion

In summary, analysis of sequence data in 119 genes across 2,548 severely obese children and 1,117 other disease controls from the UK10K project identified variants in known obesity genes, contributing to obesity in 2% of children within this cohort, in whom mutations in MC4R and leptin had been excluded. It also highlighted that GNAS mutations may be more prevalent in human obesity than previously thought, and that the spectrum of phenotypic consequences may be broader and more heterogeneous than previously described (6). Additional detailed genotype-phenotype studies will be required to further elucidate the molecular underpinnings of the physiological consequences of these variants.

Taking the information generated in this study together with the published literature, we suggest that molecular genetic investigations, including testing known obesity genes, or agnostic exome-wide or genome-wide approaches (as these become more established at the point of care), should become part of the assessment for a child presenting with severe obesity (BMI SDS > 3) in the absence of other syndromic features. Genetic studies can allow the identification of congenital leptin deficiency which is entirely treatable with recombinant leptin therapy¹⁸. Also, early reports suggest that patients with mutations that disrupt POMC signalling may be effectively treated with Setmelanotide (a MC4R agonist)¹⁹. Finally, our data suggest that focusing on very rare, deleterious variants may increase power to find genetic association. Further detailed investigation of genes that lead to obesity when deleted in mice may identify new pathophysiological mechanisms involved in human obesity that can be targeted for drug discovery.

Methods

Sample Sets

All studies were approved by the Cambridge Local Research Ethics Committee and all participants and their parents gave written informed consent. All methods were performed in accordance with the relevant laboratory/clinical guidelines and regulations.

The SCOOP cohort³ was studied as part of the UK10K consortium⁴. Data was compared to subsets within the neurodevelopmental and rare disease groups that were consented for use as controls. Details and further information about the UK10K project can be found at http://www.uk10k.org/ and in the UK10K consortium paper from 2015⁴.

We gathered the genotypes for the variant S284X (rs201622589) in 202,981 unrelated population controls with European non-Finnish ancestry from existing cohorts (UKHLS²², Fenland, EPIC Norfolk²³, CCHS^24,25,26, CGPS^24,25,26, CIHDS^24,25,26, EPIC-CVD²⁷, UK Biobank²⁸ and ExAC²⁹) and in two additional studies of obese children and healthy or thin controls^{30, 31} including one from the Leipzig Childhood Obesity Cohort³². (Supplementary Note 1)

Sequencing, Variant Calling, and Quality Control

Targeted Sequencing (TS) and Whole Exome Sequencing (WES) was performed as described elsewhere (refs 33 and 4 respectively). All UK10K WES samples from all arms of the exome study available at the time of the variant calling and SCOOP TS samples (N = 5,233 and 2,819 respectively) were called together on the non-redundant targets + /− 100 bp using multi-sample calling. Using SAMtools³⁴, a BCF file was created and the site genotype likelihoods were calculated. Variants (SNPs and Indels) were called using BCFtools. Indels were left-aligned using ‘vcf norm’ from the htslib package. Variants were filtered for sequencing and genotype quality at the site and genotype level using vcf-annotate ³⁵. Additional details in Supplementary Note 2.

Variant Annotation

All variant annotation was applied using the GRCh37 human reference. Variants were annotated with rsIDs from dbSNP 137, and allele frequencies from the final 1000Genomes Phase 1 integrated (v3) callset³⁶, the NHLBI Exome Sequencing Project (ESP) v2³⁷, and the UK10K WGS sample set⁴. The Ensembl Variant Effect Predictor (http://www.ensembl.org/info/docs/variation/vep/index.html)³⁸ v2.8 with Ensembl 66 was used to add variant consequence annotations including the predicted deleteriousness of each missense variant as predicted by SIFT^{39, 40}, PolyPhen^{41, 42}, and Condel⁴³. For the 32 known human obesity genes, only the variant consequences on the most clinically relevant transcript were considered for further analysis. For the other 87 candidate obesity genes, the most severe consequence on any transcript was retained for each variant (Supplementary Table 1). Using Sequence Ontology terms^{44, 45}, variant consequences were defined as functional (i.e. essential splice site, stop gained, stop lost, complex indel, frameshift coding, non synonymous coding, within mature miRNA, partial codon).

To identify rare variants, we used the thirteen UK10K WES sample sets that were not obese sample sets and were not included as controls in this study (Supplementary Note 1). These sample sets were processed in parallel with our cases and controls and thus provide a similar sequencing coverage and depth across the called regions. We removed variants that had a MAF > 1% across all or a MAF > 10% in any of the thirteen sample sets. We then removed variants with a MAF > 1% in any of seven additional sample sets: 1. UK10K WGS sample set⁴, 2–3. European and African American NHLBI ESP v2 sample sets ³⁷, and 4–7, the four continent sample sets (AFR, AMR, ASN, EUR) from 1000 Genomes Phase 1 integrated v3 call set³⁶. Novel variants were identified as sites not seen in any of the internal or external datasets used for MAF annotation, i.e. novel at the time of this study.

Sample quality control

Samples were identified as contaminated using a combination of two methods: VerifyBamID v1.0⁴⁶ and “fraction skewed hets”⁴. For the TS samples, the FREEMIX value was estimated using 11,250 high quality, autosomal, biallelic SNPs with an alternate AF ≥ 0.01, and a call rate ≥ 0.5 in both the TS sample set and the 1000Genomes Project Phase 1 v3³⁶. Of the 2,819 TS SCOOP samples, the 784 WES SCOOP samples, and the 1427 WES samples used as controls 37, one, and nine were excluded due to contamination respectively. Sixteen non-contaminated TS samples were excluded based on a mean sample read-depth 3 SD below the average for all samples (i.e. mean sample read-depth < 12.09). Genotype concordance for 436 WES SCOOP samples and 1,035 TS SCOOP samples for which we had both sequence and GWAS data³ was also calculated. Four WES samples and six TS samples with a concordance rate below 90% were identified and excluded. A set of highly polymorphic markers (MAF > 0.3) was genotyped and compared to the sequencing calls from each sample. Non-concordant WES samples were removed prior to variant calling and are not included in the original sequencing numbers. Eighty-one TS samples with low concordance were removed after variant calling. Three TS samples were removed due to having an extremely high genotype missing rate of > 50%.

To identify non-European samples, we calculated principal components (PCs) from the 1000Genomes Phase I integrated call set³⁶ using either EIGENSTRAT v4.2⁴⁷ or LASER 2.0⁴⁸ for the WES and TS samples respectively (Supplementary Note 3). Of the 2,676 TS samples, 837 were classified as non-European due to genetic ancestry and three were excluded due to a reported non-European ancestry resulting in 1,836 good quality TS samples of European ancestry. Of the 779 WES SCOOP samples, 37 samples were classified as non-European due to genetic ancestry resulting in 742 good quality WES SCOOP samples of European ancestry. Of the 1,418 control samples, 146 were identified as being non-European leaving 1272 high quality WES controls.

Known and cryptic relatedness was identified by estimating pairwise identity by descent using PLINK v1.07⁴⁹. Genetic relationships within the WES sample set is described in detail elsewhere⁴. We removed individuals sequentially by: (1) largest number of relationships, (2) diseased controls, non-diseased controls, cases, (3) lower mean depth of sequencing. Five SCOOP cases and 155 controls were removed resulting in 737 SCOOP WES cases and 1,117 WES controls all of high quality, unrelated, and European ancestry. A similar process was used to identify genetic relationships within the TS sample set and between the TS and WES sample sets (Supplementary Note 3). This resulted in 25 additional exclusions (18 TS cases related to WES cases and seven related within the TS sample set) for a total of 1,811 high quality, unrelated, TS samples of European ancestry.

Candidate Gene Sets

We performed database searches using keywords ‘obesity’, ‘growth’, ‘size’, ‘adipose tissue’, (details below) and manually curated the results to arrive at a set of six tiers of candidate gene with definite or likely links to obesity. The Online Mendelian Inheritance of Man (OMIM database, http://www.omim.org/) accessed in February, 2013⁵⁰ was used to identify 32 genes (Supplementary Table 1) which directly lead to human obesity. These were further categorised into two groups based on consistent clinical features: genes characterised by “Obesity alone” (Obesity Alone; n = 6), and “Obesity and developmental delay and/or dysmorphology” (Obesity and Delay; n = 26). Any putative list of candidate genes has limitations and other genes that contribute to energy homeostasis/obesity in animal models deserve interrogation in the future.

Genes that cause obesity when disrupted in rodents were identified using the Mouse Genome Informatics Database (MGI, http://www.informatics.jax.org/)⁵¹ and the Rat Genome Database (RGD, http://rgd.mcw.edu)⁵² both accessed in February 2013, as well as published research (www.ncbi.nlm.gov/Pubmed). Eighty-seven genes were associated with a growth/size phenotype when perturbed in rodent animal models. We evaluated the strength of evidence for a role of each gene in obesity phenotype and divided them into four further categories, specifically: Loss of function associated with obesity in mice (LoF Mice; n = 51); gain of function associated with obesity in mice (GoF Mice, n = 5); anorectic peptides and receptors (Anorectic Molecules, n = 7); loss of function associated with other metabolic phenotypes in mice (Complex Metabolic Effects, n = 24) (Supplementary Table 1).

Sequence validation of rare functional variants

Novel, functional variants in all 119 candidate genes were taken forward for validation by conventional Sanger sequencing (90% validation rate). Briefly, customized PCR primers were designed+/−250 bp surrounding the variant; and sequencing was performed using BigDye Terminator v3 kit (Applied BioSystems) and analysed by capillary electrophoresis on an ABI3730 DNA Analyzer platform (Applied Biosystems), according to the manufacturers’ instructions. Familial segregation analysis of variants was performed where family samples were available.

Identification of clinically-associated variants in known human obesity genes

The strategy for identification of clinically-associated variants in known human obesity genes is outlined in Fig. 1. Briefly, novel and rare variants in the known human obesity genes were filtered using the ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/). We retained novel variants and those with a ClinVar status of Pathogenic/Likely pathogenic (N = 332).

Structural Analysis of GNAS Variants

For structural analysis of the genetic variants and prediction of their impact on protein function, we modelled their location in relation to previously solved protein crystal structures of GNAS in complex with either G-protein coupled receptor (ADRB2) or downstream effector (adenylyl cyclase). Specifically, the first model represented in Fig. 3a is based on crystal structure of the active state ternary protein complex of GPCR beta-2-adrenergic receptor (ADRB2), and the nucleotide-free Gs heterotrimer, composed of Gs-α(GNAS), Gs-β, and Gs-γ subunits (ref. 20, PDB number: 3SN6, www.rcsb.org). The second model, represented in Fig. 3b, is based on complex of GNAS with the catalytic domains of mammalian adenylyl cyclase (ref. 21, PDB number: 1AZS, www.rcsb.org). The structural representations using ribbon-depicted models were generated using the Open-Source PyMOL Molecular Graphics System, Version 1.7.x Schrödinger, LLC (http://pymol.org).

Association Analyses

We implemented the optimal Sequence Kernel Association Test SKAT-O^{11, 53} with the SKAT R package v1.1.2⁵⁴ using options method = ”optimal.adj” for SKAT-O and r.corr = 1 for burden. For each gene and candidate gene set, we performed two primary tests using the burden test: 1. rare functional (Rare Func) or (2) novel functional (Novel Func). We performed secondary tests restricting either to variants that were predicted to be deleterious by at least one of the three algorithms (i.e. SIFT, PolyPhen, and Condel) (1 + del) or to variants that were predicted to be deleterious by all three algorithms (all del). For SIFT and Condel, variants were classified as deleterious if they were labelled as “deleterious”. For PolyPhen, variants were classified as deleterious if they were labelled as “probably damaging” or “damaging”. Our conservative Bonferroni adjusted significance level of the primary analyses for 119 genes and 6 gene sets was 0.05/(2 × 125) = 2.0E-4. Once considering our additional ten secondary tests, our Bonferroni adjusted significance level was 0.05/(12 × 125) = 3.3E-5. We repeated all primary and secondary tests using SKAT-O (Table 1 ; Supplementary Table 4–9, 13).

Functional studies of variants in ANGPTL6

To predict the impact of variants on the ANGPTL6 protein, we modelled their location using the crystal structure of a related protein fibrinogen in a complex with a peptide Gly-His-Pro-amide (described in Yang et al.⁵⁵, PDB number: 1LWU, www.rcsb.org). The structural representations using ribbon-depicted models were generated using the Open-Source PyMOL Molecular Graphics System, Version 1.7.x Schrödinger, LLC (http://pymol.org). N-terminal triple Flag tag was added to human ANGPTL6 cDNA cloned into a pEZ-M14 mammalian expression vector (Capital Bioscience). Mutations were introduced into this construct using QuikChange (Agilent technologies), and confirmed by Sanger sequencing. ANGPTL6 protein expression was studied by transient transfection in HEK293 cells. Media was collected 48 h – post transfection, the cell medium was centrifuged for 5 min (5,000 g at 4 °C) and the supernatants were collected. Cells were harvested prior to centrifugation for 15 min (15,000 g at 4 °C). Aliquots from the medium and cells were subjected to SDS-PAGE and immunoblot analysis. Primary antibodies (monoclonal Flag M2 antibody (Sigma) and a polyclonal antibody to Calnexin (Cell signalling)) were used at 1:1000, and secondary Horseradish peroxidase–conjugated anti-mouse or anti-rabbit IgG (Dako) antibody at 1:2000 dilution. After staining with ECL West Dura Substrate kit (Thermo Scientific), visualisation was performed on Chemidoc Digital Imager (Bio-Rad) (Supplementary Information). The relative protein secretion of ANGPTL6 for each variant was standardized to wild-type protein secretion. Experiments were performed in triplicate and analysed using an unpaired T-test with Welch’s correction.

ANGPTL6 statistical follow-up analyses

We ran gene-based analyses using SKAT-O as described above on two subsets of ANGPTL6 variants (Supplementary Table 10): (1) the one variant that resulted in a complete loss of protein secretion (S284X; rs201622589), and (2) excluding S284X. For (1), we also used a Fisher’s Exact Test. We repeated the Fisher’s Exact Test of the S284X variant including additional population controls with pre-existing genotype data and replication samples (Online Methods, Sample Sets; Supplementary Tables 11 and 12).

Power Analysis

We calculated the power to detect association to a gene region using the burden test with the Power_Logistic_R function and the haplotype dataset within the SKAT R-package⁵⁴. We performed power calculations using 500 simulations on a random 2Kb sub region. The effect sizes of the causal variants are equal to log₁₀(MAF) with a maximum effect size of 1.6 (MAF = 0.0001) and all have the same direction of effect. We limited the MAF threshold for causal variants to ≤ 0.01, 0.001, 0.0005 and varied the percentage of causal variants in the region to be between 10–90%. (More details in Supplementary Note 4).

References

El-Sayed Moustafa, J. S. & Froguel, P. From obesity genetics to the future of personalized obesity therapy. Nat Rev Endocrinol 9, 402–13 (2013).
Article CAS PubMed Google Scholar
van der Klaauw, A. A. & Farooqi, I. S. The hunger genes: pathways to obesity. Cell 161, 119–32 (2015).
Article PubMed Google Scholar
Wheeler, E. et al. Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity. Nat Genet 45, 513–7 (2013).
Article CAS PubMed PubMed Central Google Scholar
Consortium, U. K. et al. The UK10K project identifies rare variants in health and disease. Nature 526, 82–90 (2015).
Article ADS Google Scholar
Farooqi, I. S. et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348, 1085–95 (2003).
Article CAS PubMed Google Scholar
Lemos, M. C. & Thakker, R. V. GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders. Hum Mutat 36, 11–9 (2015).
Article CAS PubMed Google Scholar
Aldred, M. A. & Trembath, R. C. Activating and inactivating mutations in the human GNAS1 gene. Hum Mutat 16, 183–9 (2000).
Article CAS PubMed Google Scholar
Warner, D. R., Weng, G., Yu, S., Matalon, R. & Weinstein, L. S. A novel mutation in the switch 3 region of Gsalpha in a patient with Albright hereditary osteodystrophy impairs GDP binding and receptor activation. J Biol Chem 273, 23976–83 (1998).
Article CAS PubMed Google Scholar
Bastida Eizaguirre, M. et al. [Albright hereditary osteodystrophy: identification of a novel mutation in a family]. An Esp Pediatr 54, 598–600 (2001).
Article CAS PubMed Google Scholar
Chen, M. et al. Central nervous system imprinting of the G protein G(s)alpha and its role in metabolic regulation. Cell Metab 9, 548–55 (2009).
Article PubMed PubMed Central Google Scholar
Lee, S., Wu, M. C. & Lin, X. Optimal tests for rare variant effects in sequencing association studies. Biostatistics 13, 762–75 (2012).
Article PubMed PubMed Central Google Scholar
Moutsianas, L. et al. The power of gene-based rare variant methods to detect disease-associated variation and test hypotheses about complex disease. PLoS Genet 11, e1005165 (2015).
Article PubMed PubMed Central Google Scholar
Oike, Y. et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat Med 11, 400–8 (2005).
Article CAS PubMed Google Scholar
Kadomatsu, T., Tabata, M. & Oike, Y. Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases. FEBS J 278, 559–64 (2011).
Article CAS PubMed Google Scholar
Purcell, S. M. et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506, 185–90 (2014).
Article ADS CAS PubMed PubMed Central Google Scholar
Pinto, D. et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet 94, 677–94 (2014).
Article CAS PubMed PubMed Central Google Scholar
Krumm, N. et al. Excess of rare, inherited truncating mutations in autism. Nat Genet 47, 582–8 (2015).
Article CAS PubMed PubMed Central Google Scholar
Farooqi, I. S. et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341, 879–84 (1999).
Article CAS PubMed Google Scholar
Kuhnen, P. et al. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. N Engl J Med 375, 240–6 (2016).
Article PubMed Google Scholar
Rasmussen, S. G. et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477, 549–55 (2011).
Article ADS CAS PubMed PubMed Central Google Scholar
Tesmer, J. J., Sunahara, R. K., Gilman, A. G. & Sprang, S. R. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS. Science 278, 1907–16 (1997).
Article ADS CAS PubMed Google Scholar
Lynn, P. Sample design for Understanding Society. Understanding Society Working Paper Series 2009–01(2009).
Day, N. et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 80(Suppl 1), 95–103 (1999).
MathSciNet PubMed Google Scholar
Kamstrup, P. R., Tybjaerg-Hansen, A., Steffensen, R. & Nordestgaard, B. G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301, 2331–9 (2009).
Article CAS PubMed Google Scholar
Nordestgaard, B. G., Benn, M., Schnohr, P. & Tybjaerg-Hansen, A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298, 299–308 (2007).
Article CAS PubMed Google Scholar
Varbo, A. et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 61, 427–36 (2013).
Article CAS PubMed Google Scholar
Danesh, J. et al. EPIC-Heart: the cardiovascular component of a prospective study of nutritional, lifestyle and biological factors in 520,000 middle-aged participants from 10 European countries. Eur J Epidemiol 22, 129–41 (2007).
Article PubMed Google Scholar
Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 12, e1001779 (2015).
Article PubMed PubMed Central Google Scholar
Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org) ([September, 2015]).
Hinney, A. et al. Genome Wide Association (GWA) Study for Early Onset Extreme Obesity Supports the Role of Fat Mass and Obesity Associated Gene (FTO) Variants. PLoS ONE 2, e1361 (2007).
Article ADS PubMed PubMed Central Google Scholar
Quante, M. et al. The LIFE child study: a life course approach to disease and health. BMC Public Health 12, 1021 (2012).
Article PubMed PubMed Central Google Scholar
Korner, A., Berndt, J., Stumvoll, M., Kiess, W. & Kovacs, P. TCF7L2 gene polymorphisms confer an increased risk for early impairment of glucose metabolism and increased height in obese children. J Clin Endocrinol Metab 92, 1956–60 (2007).
Article PubMed Google Scholar
Grozeva, D. et al. De novo loss-of-function mutations in SETD5, encoding a methyltransferase in a 3p25 microdeletion syndrome critical region, cause intellectual disability. Am J Hum Genet 94, 618–24 (2014).
Article CAS PubMed PubMed Central Google Scholar
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–9 (2009).
Article PubMed PubMed Central Google Scholar
Danecek, P. et al. The variant call format and VCFtools. Bioinformatics 27, 2156–8 (2011).
Article CAS PubMed PubMed Central Google Scholar
Genomes Project, C. et al. A map of human genome variation from population-scale sequencing. Nature 467, 1061–73 (2010).
Article ADS Google Scholar
Tennessen, J. A. et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337, 64–9 (2012).
Article ADS CAS PubMed PubMed Central Google Scholar
McLaren, W. et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069–70 (2010).
Article CAS PubMed PubMed Central Google Scholar
Ng, P. C. & Henikoff, S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31, 3812–4 (2003).
Article CAS PubMed PubMed Central Google Scholar
Ng, P. C. & Henikoff, S. Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7, 61–80 (2006).
Article CAS PubMed Google Scholar
Sunyaev, S., Ramensky, V. & Bork, P. Towards a structural basis of human non-synonymous single nucleotide polymorphisms. Trends Genet 16, 198–200 (2000).
Article CAS PubMed Google Scholar
Sunyaev, S. et al. Prediction of deleterious human alleles. Hum Mol Genet 10, 591–7 (2001).
Article CAS PubMed Google Scholar
Gonzalez-Perez, A. & Lopez-Bigas, N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet 88, 440–9 (2011).
Article CAS PubMed PubMed Central Google Scholar
Eilbeck, K. et al. The Sequence Ontology: a tool for the unification of genome annotations. Genome Biol 6, R44 (2005).
Article PubMed PubMed Central Google Scholar
Mungall, C. J., Batchelor, C. & Eilbeck, K. Evolution of the Sequence Ontology terms and relationships. J Biomed Inform 44, 87–93 (2011).
Article PubMed Google Scholar
Jun, G. et al. Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data. Am J Hum Genet 91, 839–48 (2012).
Article CAS PubMed PubMed Central Google Scholar
Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38, 904–9 (2006).
Article CAS PubMed Google Scholar
Wang, C., Zhan, X., Liang, L., Abecasis, G. R. & Lin, X. Improved ancestry estimation for both genotyping and sequencing data using projection procrustes analysis and genotype imputation. Am J Hum Genet 96, 926–37 (2015).
Article CAS PubMed PubMed Central Google Scholar
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81, 559–75 (2007).
Article CAS PubMed PubMed Central Google Scholar
Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD), (http://omim.org/) (February, 2013).
The Mouse Genome Database (MGD), Mouse Genome Informatics. The Jackson Laboratory, Bar Harbor, Maine. http://www.informatics.jax.org (February, 2013).
The Rat Genome Browser (RGD), Rat Genome Database Web Site. Medical College of Wisconsin, Milwaukee, Wisconsin http://rgd.mcw.edu/ (February, 2013).
Wu, M. C. et al. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet 89, 82–93 (2011).
Article CAS PubMed PubMed Central Google Scholar
Seunggeun Lee, with contributions from Larisa Miropolsky and Michael Wu. SKAT: SNP-Set(Sequence) Kernel Association Test.. R package version 1.1.2. http://CRAN.R-project.org/package=SKAT (2015).
Yang, Z. et al. Crystal structure of fragment D from lamprey fibrinogen complexed with the peptide Gly-His-Arg-Pro-amide. Biochemistry 41, 10218–24 (2002).
Article CAS PubMed Google Scholar

Download references

Acknowledgements

We are indebted to the patients and their families for their participation and to the physicians involved in the Genetics of Obesity Study (GOOS). This work was supported by the Wellcome Trust (ISF, IB) (098497/Z/12/Z; WT098051), Medical Research Council (ISF, SOR) (MRC_MC_UU_12012/5), NIHR Cambridge Biomedical Research Centre (ISF, IB, SOR), Bernard Wolfe Health Neuroscience Endowment (ISF), European Research Council (ISF) and NIH grant DK064265 (GLM), the European Community’s Seventh Framework Programme (FP7/2007–2013) project Beta-JUDO n°279153 (ISF, AK). This study comprises one arm of the UK10K Consortium (WT091310). The UK Household Longitudinal Study is led by the Institute for Social and Economic Research at the University of Essex and funded by the Economic and Social Research Council. The survey was conducted by NatCen and the genome-wide scan data were analysed and deposited by the Wellcome Trust Sanger Institute. Information on how to access the data can be found on the Understanding Society website https://www.understandingsociety.ac.uk/. AH and JH were funded by the German Ministry for Education and Research (National Genome Research Net-Plus 01GS0820), the German Research Foundation (DFG; HI865/2-1), the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreements n°245009 and n°262055. We thank participants and staff of the Copenhagen City Heart Study, Copenhagen Ischemic Heart Disease Study, and the Copenhagen General Population Study for their important contributions (CCHS, CGPS, CIHDS). CHD case ascertainment and validation, genotyping, and clinical chemistry assays in EPIC-CVD were supported by grants awarded to the University of Cambridge from the EU Framework Programme 7 (HEALTH-F2-2012-279233), the UK Medical Research Council (G0800270) and British Heart Foundation (SP/09/002), the European Research Council (268834), the UK National Institute for Health Research Cambridge Biomedical Research Centre, Merck and Pfizer. We thank all EPIC participants and staff for their contribution to the study, the laboratory teams at the Medical Research Council Epidemiology Unit for sample management and Cambridge Genomic Services for genotyping, Sarah Spackman for data management, and the team at the EPIC-CVD Coordinating Centre for study coordination and administration (EPIC-CVD). JD is supported by a British Heart Foundation Professorship, NIHR Senior Investigator, European Research Council Senior Investigator. Leipzig LIFE Child as part of the Leipzig Childhood Obesity cohort was funded by the European Union, by the European Regional Development Fund (ERFD) by means of the Free State of Saxony within the framework of the excellence initiative. This research has been conducted using the UK Biobank Resource.

Author information

Audrey E. Hendricks and Elena G. Bochukova contributed equally to this work.

Authors and Affiliations

Wellcome Trust Sanger Institute, Cambridge, UK
Audrey E. Hendricks, Gaëlle Marenne, Eleanor Wheeler, Dawn Muddyman, Shane McCarthy, John Danesh, Ioanna Tachmazidou, Eleftheria Zeggini, Inês Barroso, Carl A. Anderson, Senduran Bala, Jeffrey C. Barrett, Keren Carss, Peter Clapham, Guy Coates, Tony Coxa, Allan Daly, Petr Danecek, Richard Durbin, Sarah Edkins, Peter Ellis, Christopher S. Franklin, Matthias Geihs, Jie Huang, Tim Hubbard, Matthew E. Hurles, Valentina Iotchkova, David K. Jackson, Chris Joyce, Thomas Keane, Karen Kennedy, Margriet van Kogelenberg, Anja Kolb-Kokocinski, Cordelia Langford, Margarida Lopes, John Maslen, Yasin Memari, James Morris, Aarno Palotie, Kalliope Panoutsopoulou, Felicity Payne, Michael A. Quail, Karola Rehnström, Stephan Schiffels, Eva Serra, So-Youn Shin, Carol Smee, Nicole Soranzo, Lorraine Southam, Jim Stalker, Parthiban Vijayarangakannan, Klaudia Walter & Kim Wong
Department of Mathematical and Statistical Sciences, University of Colorado-Denver, Denver, CO, 80204, USA
Audrey E. Hendricks
University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, UK
Elena G. Bochukova, Julia M. Keogh, Neli Atanassova, Rebecca Bounds, Vanisha Mistry, Elana Henning, Sofia Papadia, Sofie Ashford, Sumedha Garg, Alexandra Kwasniewska, Stephen O’Rahilly, Inês Barroso, I. Sadaf Farooqi, Krishna Chatterjee, Konrad J. Karczewski, Victoria Parker, David B. Savage, Nadia Schoenmakers & Robert K. Semple
The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
Elena G. Bochukova & Konrad J. Karczewski
Center for Pediatric Research, University Children’s Hospital Leipzig, Leipzig, Germany
Antje Körner
IFB Adiposity Diseases Medical Faculty, University of Leipzig, Leipzig, Germany
Antje Körner & Konrad J. Karczewski
Department of Child and Adolescent Psychiatry, Psychotherapy, and Psychosomatics, University Hospital Essen and University of Duisburg-Essen, Essen, Germany
Anke Hinney & Johannes Hebebrand
MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK
Robert A. Scott, Claudia Langenberg, Nick J. Wareham, Jane Kaye & John R. B. Perry
Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
Praveen Surendran, Joanna M. Howson, Adam S. Butterworth & John Danesh
The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics, University of Cambridge, Cambridge, UK
Adam S. Butterworth & John Danesh
Department of Clinical Biochemistry and The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark
Børge G Nordestgaard, Sune F Nielsen & Shoaib Afzal
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Børge G Nordestgaard, Sune F Nielsen & Shoaib Afzal
Department of Chemistry & Biochemistry, University of California Santa Cruz, Santa Cruz, CA, 95064, USA
Glenn L. Millhauser & Rafael I. Palomino
Institute for Social and Economic Research, University of Essex, Colchester, UK
Michaela Benzeval, Jonathan Burton, Nicholas Buck, Annette Jäckle, Meena Kumari, Heather Laurie, Peter Lynn, Stephen Pudney & Birgitta Rabe
University of Warwick, Warwick, UK
Dieter Wolke
Department of Pathology, King Abdulaziz Medical City, P.O. Box 22490, Riyadh, 11426, Saudi Arabia
Saeed Al Turki
Department of Psychiatry, Trinity Centre for Health Sciences, St James Hospital, James’s Street, Dublin, 8, Ireland
Richard Anney & Louise Gallagher
Genetics and Genomic Medicine and Birth Defects Research Centre, UCL Institute of Child Health, London, WC1N 1EH, UK
Dinu Antony, Phil Beales, Hannah M. Mitchison, Peter Scambler, Miriam Schmidts & Richard H. Scott
Departments of Health Sciences and Genetics, University of Leicester, Leicester, LE1 7RH, UK
María Soler Artigas, Martin D. Tobin & Louise V. Wain
Division of Developmental Disabilities, Department of Psychiatry, Queen’s University, Kingston, Ontario, N6C 0A7, Canada
Muhammad Ayub
Department of Cardiovascular Medicine and Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK
Jamie Bentham, Shoumo Bhattacharyaa & Catherine Cosgrove
European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK
Ewan Birney, Ian Dunham, Paul Flicek, Valentina Iotchkova & Graham R. S. Ritchie
Division of Psychiatry, The University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, EH10 5HF, UK
Douglas Blackwooda & Andrew G. McKechanie
Academic Laboratory of Medical Genetics, Box 238, Lv 6 Addenbrooke’s Treatment Centre, Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK
Martin Bobrow, Detelina Grozeva, F. Lucy Raymond, Olivera Spasic-Boskovic, Crispian Wilson & Scott G. Wilson
Department of Child Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, 16 De Crespigny Park, London, SE5 8AF, UK
Patrick F. Bolton & Sarah Curran
NIHR BRC for Mental Health, Institute of Psychiatry, Psychology and Neuroscience and SLaM NHS Trust, King’s College London, London, UK. 16 De Crespigny Park, London, SE5 8AF, UK
Patrick F. Bolton & Gerome Breen
MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Denmark Hill, London, SE5 8AF, UK
Patrick F. Bolton, Gerome Breen, David A. Collier & Peter McGuffin
North East Thames Regional Genetics Service, Great Ormond Street Hospital NHS Foundation Trust, London, WC1N 3JH, UK
Chris Boustred
Dubowitz Neuromuscular Centre, UCL Institute of Child Health & Great Ormond Street Hospital, London, WC1N 1EH, UK
Sebahattin Cirak, A. Reghan Foley, Francesco Muntoni, Elizabeth Stevens & Tamieka Whyte
Leeds Genetics Laboratory, St James University Hospital, Beckett Street, Leeds, LS9 7TF, UK
Ruth Charlton & Rachel L. Robinson
Department of Haematology, University of Cambridge, Long Road, Cambridge, CB2 0PT, UK
Lu Chen & Nicole Soranzo
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, H3A 1A2, Canada
Antonio Ciampia, Celia M. T. Greenwood, J. Brent Richards, Jianping Sun & ChangJiang Xu
Institut für Humangenetik, Uniklinik Köln, Kerpener Strasse 34, 50931, Köln, Germany
Sebahattin Cirak
The Department of Twin Research & Genetic Epidemiology, King’s College London, St Thomas’ Campus, Lambeth Palace Road, London, SE1 7EH, UK
Gail Clement, Deborah Hart, Pirro Hysi, Genevieve Lachance, Massimo Mangino, Alireza Moayyeri, John R. B. Perry, Lydia Quaye, J. Brent Richards, Kerrin S. Small, Timothy D. Spector, Gabriela Surdulescu, Ana M. Valdes, Kirsten Ward & Feng Zhang
Medical Genetics, Institute for Maternal and Child Health IRCCS “Burlo Garofolo”, 34100, Trieste, Italy
Massimiliano Coccaa
Department of Medical, Surgical and Health Sciences, University of Trieste, 34100, Trieste, Italy
Massimiliano Coccaa
Lilly Research Laboratories, Eli Lilly & Co. Ltd., Erl Wood Manor, Sunninghill Road, Windlesham, GU20 6PH, UK
David A. Collier
MRC Centre for Neuropsychiatric Genetics & Genomics, Institute of Psychological Medicine & Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, CF24 4HQ, UK
Nick Craddock, Peter Holmans, Michael J. Owen, James T. R. Walters & Hywel J. Williams
Sheffield Diagnostic Genetics Service, Sheffield Childrens’ NHS Foundation Trust, Western Bank, Sheffield, S10 2TH, UK
Lucy Crooks
University of Sussex, Brighton, BN1 9RH, UK
Sarah Curran
Sussex Partnership NHS Foundation Trust, Swandean, Arundel Road, Worthing, BN13 3EP, UK
Sarah Curran
University College London (UCL), UCL Genetics Institute, Darwin Building, Gower Street, London, WC1E 6BT, UK
David Curtis
Bristol Genetic Epidemiology Laboratories, School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol, BS8 2BN, UK
Ian N. M. Day
Computational Biology & Genomics, Biogen Idec, 14 Cambridge Center, Cambridge, Massachusetts, 02142, USA
Aaron Day-Williams
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Wolfson Medical School Building, University Avenue, Glasgow, G12 8QQ, UK
Anna Dominiczak
Department of Medical and Molecular Genetics, Division of Genetics and Molecular Medicine, King’s College London School of Medicine, Guy’s Hospital, London, SE1 9RT, UK
Thomas Down & Tim Hubbard
BGI-Shenzhen, Shenzhen, 518083, China
Yuanping Du, Xiaosen Guo, Xueqin Guo, Liren Huang, Yingrui Li, Jieqin Liang, Hong Lin, Jing Tian, Guangbiao Wang, Jun Wang, Yu Wang & Pingbo Zhang
University College London (UCL) Department of Genetics, Evolution & Environment (GEE), Gower Street, London, WC1E 6BT, UK
Rosemary Ekong & Sue Povey
MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol, BS8 2BN, UK
David M. Evansa, Tom R. Gaunt, John P. Kemp, Lavinia Paternoster, Hashem A. Shihab, So-Youn Shin, George Davey Smith, Beate St Pourcain & Nicholas J. Timpson
University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, 4102, Australia
David M. Evansa, John P. Kemp, Peter M. Visscher & Jian Yang
MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, at the University of Edinburgh, Western General Hospital, Edinburgh, EH4 2XU, UK
David R. Fitzpatrick & Kathleen A. Williamson
The Genome Centre, John Vane Science Centre, Queen Mary, University of London, Charterhouse Square, London, EC1M 6BQ, UK
James Floyd & Alireza Moayyeri
Cardiovascular Genetics, BHF Laboratories, Rayne Building, Institute of Cardiovascular Sciences, University College London, London, WC1E 6JJ, UK
Marta Futema & Steve E. Humphries
UCLA David Geffen School of Medicine, Los Angeles, California, 90095, USA
Daniel Geschwind
Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada
Celia M. T. Greenwood, Rui Li, J. Brent Richards, Jianping Sun, ChangJiang Xu & Hou-Feng Zheng
Department of Human Genetics, McGill University, Montreal, Quebec, H3A 1B1, Canada
Celia M. T. Greenwood, Rui Li, J. Brent Richards & Hou-Feng Zheng
Department of Oncology, McGill University, Montreal, Quebec, H2W 1S6, Canada
Celia M. T. Greenwood
HeLEX – Centre for Health, Law and Emerging Technologies, Nuffield Department of Population Health, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK
Heather Griffin
Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, DK-2200, Copenhagen, Denmark
Xiaosen Guo & Jun Wang
University College London (UCL), Molecular Psychiatry Laboratory, Division of Psychiatry, Gower Street, London, WC1E 6BT, UK
Hugh Gurling & Sally I. Sharp
Adaptive Biotechnologies Corporation, Seattle, Washington, 98102, USA
Bryan Howie
Human Genetics Research Centre, St George’s University of London, London, SW17 0RE, UK
Yalda Jamshidi
Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, 02114, USA
Monkol Lek & Daniel G. MacArthur
Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, 02142, USA
Daniel G. MacArthur
National Cancer Research Institute, Angel Building, 407 St John Street, London, EC1V 4AD, UK
Karen Kennedy
Genetic Alliance UK, 4D Leroy House, 436 Essex Road, London, N1 3QP, UK
Alastair Kent
SW Thames Regional Genetics Lab, St George’s University, Cranmer Terrace, London, SW17 0RE, UK
Farrah Khawaja & Rohan Taylor
Schools of Mathematics and Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol, BS8 2BN, UK
Daniel Lawson
Behavioural and Brain Sciences Unit, UCL Institute of Child Health, London, WC1N 1EH, UK
Irene Lee & David Skuse
Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, H3A 1B1, Canada
Rui Li, J. Brent Richards & Hou-Feng Zheng
BGI-Europe, London, EC2M 4YE, UK
Ryan Liu
National Institute for Health and Welfare (THL), Helsinki, FI-00271, Finland
Jouko Lönnqvist, Tiina Paunio, Olli Pietilainen & Jaana Suvisaari
Institute of Cardiovascular Science, University College London, Gower Street, London, WC1E 6BT, UK
Luis R. Lopes & Petros Syrris
Cardiovascular Centre of the University of Lisbon, Faculty of Medicine, University of Lisbon, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal
Luis R. Lopes
Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford, OX3 7BN, UK
Margarida Lopes, Jonathan Marchini & Lorraine Southam
Illumina Cambridge Ltd, Chesterford Research Park, Cambridge, CB10 1XL, UK
Margarida Lopes
National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s and St Thomas’ Foundation Trust, London, SE1 9RT, UK
Massimo Mangino
Department of Statistics, University of Oxford, 1 South Parks Road, Oxford, OX1 3TG, UK
Jonathan Marchini
Department of Genetics, Harvard Medical School, Boston, Massachusetts, 02115, USA
Iain Mathieson
The Patrick Wild Centre, The University of Edinburgh, Edinburgh, EH10 5HF, UK
Andrew G. McKechanie
Department of Medical Sciences, University of Torino, 10124, Torino, Italy
Nicola Migone
Institute of Health Informatics, Farr Institute of Health Informatics Research, University College London (UCL), 222 Euston Road, London, NW1 2DA, UK
Andrew Morris
Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, 9 Little France Road, Edinburgh, EH16 4UX, UK
Andrew Morris
Department of Mathematics, Université de Québec À Montréal, Montréal, Québec, H3C 3P8, Canada
Karim Oualkacha
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, FI-00014, Finland
Aarno Palotie & Olli Pietilainen
Program in Medical and Population Genetics and Genetic Analysis Platform, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, 02132, USA
Aarno Palotie
Institute of Neuroscience, Henry Wellcome Building for Neuroecology, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
Jeremy R. Parr
University of Helsinki, Department of Psychiatry, Helsinki, FI-00014, Finland
Tiina Paunio
North West Thames Regional Genetics Service, Kennedy-Galton Centre, Northwick Park Hospital, Watford Road, Harrow, HA1 3UJ, UK
Stewart J. Payne
University College London (UCL) Genetics Institute (UGI), Gower Street, London, WC1E 6BT, UK
Vincent Plagnol
Connective Tissue Disorders Service, Sheffield Diagnostic Genetics Service, Sheffield Children’s NHS Foundation Trust, Western Bank, Sheffield, S10 2TH, UK
Rebecca C. Pollitt
Centre for Genomic and Experimental Medicine, Institute of Genetics and Experimental Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
David J. Porteous
Molecular Genetics, Viapath at Guy’s Hospital, London, SE1 9RT, UK
Cheryl K. Ridout
ALSPAC & School of Social and Community Medicine, University of Bristol, Oakfield House, Oakfield Grove, Clifton, Bristol, BS8 2BN, UK
Susan Ring
Human Genetics Department, Radboudumc and Radboud Institute for Molecular Life Sciences (RIMLS), Geert Grooteplein 25, Nijmegen, 6525, HP, The Netherlands
Miriam Schmidts
Department of Clinical Genetics, Great Ormond Street Hospital, London, WC1N 3JH, UK
Richard H. Scott
Clinical Genetics, Guy’s & St Thomas’ NHS Foundation Trust, London, SE1 9RT, UK
Adam Shaw
Mackenzie Building, Kirsty Semple Way, Ninewells Hospital and Medical School, Dundee, DD2 4RB, UK
Blair H. Smith
Institute of Medical Sciences, University of Aberdeen, Aberdeen, AB25 2ZD, UK
David St Clair
School of Oral and Dental Sciences, University of Bristol, Lower Maudlin Street, Bristol, BS1 2LY, UK
Beate St Pourcain
School of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol, BS8 1TU, UK
Beate St Pourcain
National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit, Glenfield Hospital, Leicester, LE3 9QP, UK
Martin D. Tobin
Maritime Medical Genetics Service, 5850/5980 University Avenue, PO Box 9700, Halifax, Nova Scotia, B3K 6R8, Canada
Anthony M. Vandersteen
Queensland Brain Institute, University of Queensland, Brisbane, Queensland, 4072, Australia
Peter M. Visscher & Jian Yang
Princess Al Jawhara Albrahim Center of Excellence in the Research of Hereditary Disorders, King Abdulaziz University, P.O. Box 80200, Jeddah, 21589, Saudi Arabia
Jun Wang
Macau University of Science and Technology, Avenida Wai long, Taipa, Macau, 999078, China
Jun Wang
Department of Medicine and State Key Laboratory of Pharmaceutical Biotechnology, University of Hong Kong, 21 Sassoon Road, Pok Fu Lam, Hong Kong
Jun Wang
The Centre for Translational Omics – GOSgene, UCL Institute of Child Health, London, WC1N 1EH, UK
Hywel J. Williams
School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, 6009, Australia
Scott G. Wilson
Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia
Scott G. Wilson
Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark
Kim Overvad
Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark
Kim Overvad
Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark
Anne Tjønneland & Conchi Moreno-Iribas
INSERM, Centre for Research in Epidemiology and Population Health (CESP), U1018, Nutrition, Hormones, and Women’s Health Team, Institut Gustave Roussy, Villejuif, France
Francoise Clavel-Chapelon
Division of Cancer Genetic Epidemiology, German Cancer Research Centre (DKFZ), im Neuenheimer Feld 581, 69121, Heidelberg, Germany
Rudolf Kaaks
Department of Epidemiology, German Institute of Human Nutrition (DIfE), PotsdamRehbrücke, Germany
Heiner Boeing
WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece
Antonia Trichopoulou
Hellenic Health Foundation, Athens, Greece
Antonia Trichopoulou
IARC, Lyon, France
Pietro Ferrari
Molecular and Nutritional Epidemiology Unit, Centro per lo Studio e la Prevenzione Oncologica-Scientific Institute of Tuscany, Florence, Italy
Domenico Palli
Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Vittorio Krogha
Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy
Salvatore Panico
Cancer Registry and Histopathology Unit, Civic- M.P.Arezzo Hospital, ASP Ragusa, Italy
Rosario Tuminoa
Human Genetics Foundation, Turin, Italy
Giuseppe Matullo & Nicola Roberts
Department of Medical Sciences, University of Turin, Turin, Italy
Giuseppe Matullo
Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
Jolanda Boer
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
Yvonne van. der. Schouw
Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway
Elisabete Weiderpass
Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway
Elisabete Weiderpass & Mattia Calissanoa
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
Elisabete Weiderpass
Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland
Elisabete Weiderpass
Public Health Directorate, Asturias, Spain
J. Ramon Quiros
Public Health Institute of Navarra, Pamplona, Spain
María-José Sánchez
Red de Investigación en Servicios de Salud en Enfermedades Crónicas, Madrid, Spain
María-José Sánchez & Conchi Moreno-Iribas
Epidemiology Department, Murcia Health Authority, Murcia, Spain
Carmen Navarro
Centro de Investigación Biomédica en red en Epidemiología y Salud Pública, Barcelona, Spain
Carmen Navarro
Public Health Division of Gipuzkoa, Instituto Bio-Donostia, Basque Government, CIBERESP, Gipuzkoa, Spain
Larraitz Arriola
CRR, Lund University, 20502, Malmö, Sweden
Olle Melander
Department of Public Health and Clinical Medicine, Family Medicine, Umeå University, Umeå, Sweden
Patrik Wennberg
Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
Timothy J. Key
German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany
Elio Riboli

Author notes

A comprehensive list of consortium members appears at the end of the paper.

Authors

Audrey E. Hendricks
View author publications
You can also search for this author in PubMed Google Scholar
Elena G. Bochukova
View author publications
You can also search for this author in PubMed Google Scholar
Gaëlle Marenne
View author publications
You can also search for this author in PubMed Google Scholar
Julia M. Keogh
View author publications
You can also search for this author in PubMed Google Scholar
Neli Atanassova
View author publications
You can also search for this author in PubMed Google Scholar
Rebecca Bounds
View author publications
You can also search for this author in PubMed Google Scholar
Eleanor Wheeler
View author publications
You can also search for this author in PubMed Google Scholar
Vanisha Mistry
View author publications
You can also search for this author in PubMed Google Scholar
Elana Henning
View author publications
You can also search for this author in PubMed Google Scholar
Antje Körner
View author publications
You can also search for this author in PubMed Google Scholar
Dawn Muddyman
View author publications
You can also search for this author in PubMed Google Scholar
Shane McCarthy
View author publications
You can also search for this author in PubMed Google Scholar
Anke Hinney
View author publications
You can also search for this author in PubMed Google Scholar
Johannes Hebebrand
View author publications
You can also search for this author in PubMed Google Scholar
Robert A. Scott
View author publications
You can also search for this author in PubMed Google Scholar
Claudia Langenberg
View author publications
You can also search for this author in PubMed Google Scholar
Nick J. Wareham
View author publications
You can also search for this author in PubMed Google Scholar
Praveen Surendran
View author publications
You can also search for this author in PubMed Google Scholar
Joanna M. Howson
View author publications
You can also search for this author in PubMed Google Scholar
Adam S. Butterworth
View author publications
You can also search for this author in PubMed Google Scholar
John Danesh
View author publications
You can also search for this author in PubMed Google Scholar
Børge G Nordestgaard
View author publications
You can also search for this author in PubMed Google Scholar
Sune F Nielsen
View author publications
You can also search for this author in PubMed Google Scholar
Shoaib Afzal
View author publications
You can also search for this author in PubMed Google Scholar
Sofia Papadia
View author publications
You can also search for this author in PubMed Google Scholar
Sofie Ashford
View author publications
You can also search for this author in PubMed Google Scholar
Sumedha Garg
View author publications
You can also search for this author in PubMed Google Scholar
Glenn L. Millhauser
View author publications
You can also search for this author in PubMed Google Scholar
Rafael I. Palomino
View author publications
You can also search for this author in PubMed Google Scholar
Alexandra Kwasniewska
View author publications
You can also search for this author in PubMed Google Scholar
Ioanna Tachmazidou
View author publications
You can also search for this author in PubMed Google Scholar
Stephen O’Rahilly
View author publications
You can also search for this author in PubMed Google Scholar
Eleftheria Zeggini
View author publications
You can also search for this author in PubMed Google Scholar
Inês Barroso
View author publications
You can also search for this author in PubMed Google Scholar
I. Sadaf Farooqi
View author publications
You can also search for this author in PubMed Google Scholar

Consortia

Understanding Society Scientific Group

Michaela Benzeval
, Jonathan Burton
, Nicholas Buck
, Annette Jäckle
, Meena Kumari
, Heather Laurie
, Peter Lynn
, Stephen Pudney
, Birgitta Rabe
& Dieter Wolke

EPIC-CVD Consortium

Kim Overvad
, Anne Tjønneland
, Francoise Clavel-Chapelon
, Rudolf Kaaks
, Heiner Boeing
, Antonia Trichopoulou
, Pietro Ferrari
, Domenico Palli
, Vittorio Krogha
, Salvatore Panico
, Rosario Tuminoa
, Giuseppe Matullo
, Jolanda Boer
, Yvonne van. der. Schouw
, Elisabete Weiderpass
, J. Ramon Quiros
, María-José Sánchez
, Carmen Navarro
, Conchi Moreno-Iribas
, Larraitz Arriola
, Olle Melander
, Patrik Wennberg
, Timothy J. Key
& Elio Riboli

UK10K Consortium

Saeed Al Turki
, Carl A. Anderson
, Richard Anney
, Dinu Antony
, María Soler Artigas
, Muhammad Ayub
, Senduran Bala
, Jeffrey C. Barrett
, Phil Beales
, Jamie Bentham
, Shoumo Bhattacharyaa
, Ewan Birney
, Douglas Blackwooda
, Martin Bobrow
, Patrick F. Bolton
, Chris Boustred
, Gerome Breen
, Mattia Calissanoa
, Keren Carss
, Ruth Charlton
, Krishna Chatterjee
, Lu Chen
, Antonio Ciampia
, Sebahattin Cirak
, Peter Clapham
, Gail Clement
, Guy Coates
, Massimiliano Coccaa
, David A. Collier
, Catherine Cosgrove
, Tony Coxa
, Nick Craddock
, Lucy Crooks
, Sarah Curran
, David Curtis
, Allan Daly
, Petr Danecek
, Ian N. M. Day
, Aaron Day-Williams
, Anna Dominiczak
, Thomas Down
, Yuanping Du
, Ian Dunham
, Richard Durbin
, Sarah Edkins
, Rosemary Ekong
, Peter Ellis
, David M. Evansa
, David R. Fitzpatrick
, Paul Flicek
, James Floyd
, A. Reghan Foley
, Christopher S. Franklin
, Marta Futema
, Louise Gallagher
, Tom R. Gaunt
, Matthias Geihs
, Daniel Geschwind
, Celia M. T. Greenwood
, Heather Griffin
, Detelina Grozeva
, Xiaosen Guo
, Xueqin Guo
, Hugh Gurling
, Deborah Hart
, Peter Holmans
, Bryan Howie
, Jie Huang
, Liren Huang
, Tim Hubbard
, Steve E. Humphries
, Matthew E. Hurles
, Pirro Hysi
, Valentina Iotchkova
, David K. Jackson
, Yalda Jamshidi
, Chris Joyce
, Konrad J. Karczewski
, Jane Kaye
, Thomas Keane
, John P. Kemp
, Karen Kennedy
, Alastair Kent
, Farrah Khawaja
, Margriet van Kogelenberg
, Anja Kolb-Kokocinski
, Genevieve Lachance
, Cordelia Langford
, Daniel Lawson
, Irene Lee
, Monkol Lek
, Rui Li
, Yingrui Li
, Jieqin Liang
, Hong Lin
, Ryan Liu
, Jouko Lönnqvist
, Luis R. Lopes
, Margarida Lopes
, Daniel G. MacArthur
, Massimo Mangino
, Jonathan Marchini
, John Maslen
, Iain Mathieson
, Peter McGuffin
, Andrew M. McIntosh
, Andrew G. McKechanie
, Andrew McQuillin
, Yasin Memari
, Sarah Metrustry
, Nicola Migone
, Josine L. Min
, Hannah M. Mitchison
, Alireza Moayyeri
, Andrew Morris
, James Morris
, Francesco Muntoni
, Kate Northstone
, Michael C. O’Donovan
, Alexandros Onoufriadis
, Karim Oualkacha
, Michael J. Owen
, Aarno Palotie
, Kalliope Panoutsopoulou
, Victoria Parker
, Jeremy R. Parr
, Lavinia Paternoster
, Tiina Paunio
, Felicity Payne
, Stewart J. Payne
, John R. B. Perry
, Olli Pietilainen
, Vincent Plagnol
, Rebecca C. Pollitt
, David J. Porteous
, Sue Povey
, Michael A. Quail
, Lydia Quaye
, F. Lucy Raymond
, Karola Rehnström
, J. Brent Richards
, Cheryl K. Ridout
, Susan Ring
, Graham R. S. Ritchie
, Nicola Roberts
, Rachel L. Robinson
, David B. Savage
, Peter Scambler
, Stephan Schiffels
, Miriam Schmidts
, Nadia Schoenmakers
, Richard H. Scott
, Robert K. Semple
, Eva Serra
, Sally I. Sharp
, Adam Shaw
, Hashem A. Shihab
, So-Youn Shin
, David Skuse
, Kerrin S. Small
, Carol Smee
, Blair H. Smith
, George Davey Smith
, Nicole Soranzo
, Lorraine Southam
, Olivera Spasic-Boskovic
, Timothy D. Spector
, David St Clair
, Beate St Pourcain
, Jim Stalker
, Elizabeth Stevens
, Jianping Sun
, Gabriela Surdulescu
, Jaana Suvisaari
, Petros Syrris
, Rohan Taylor
, Jing Tian
, Nicholas J. Timpson
, Martin D. Tobin
, Ana M. Valdes
, Anthony M. Vandersteen
, Parthiban Vijayarangakannan
, Peter M. Visscher
, Louise V. Wain
, Klaudia Walter
, James T. R. Walters
, Guangbiao Wang
, Jun Wang
, Yu Wang
, Kirsten Ward
, Tamieka Whyte
, Hywel J. Williams
, Kathleen A. Williamson
, Crispian Wilson
, Scott G. Wilson
, Kim Wong
, ChangJiang Xu
, Jian Yang
, Feng Zhang
, Pingbo Zhang
& Hou-Feng Zheng

Contributions

I.B., I.S.F., A.E. and E.G.B. designed the study, analysed the data and wrote the paper. J.M.K., R.B., S.A., E.H. contributed to recruitment and consenting of the cohort; N.A., V.M., A.K., S.P., S.G. to validation of genetic findings in family studies and functional studies; G.M., E.W., I.T., E.Z. contributed to data analysis and G.L.M., R.I.P., S.O.R., to data collection and/or analysis. A.K., J.K. contributed data in Leipzig children. A.H., J.H., R.A.S., C.L., N.J.W., P.S., J.M.M.H., A.S.B., J.D., B.G.N., S.F.N., S.A., Understanding Society Scientific Group, EPIC-CVD Consortium contributed data for the ANGPTL6 (p.S284X) variant. Targeted and whole-exome sequencing was performed as part of the UK10K consortium. All authors reviewed and contributed to the final version of the paper.

Corresponding authors

Correspondence to Inês Barroso or I. Sadaf Farooqi.

Ethics declarations

Competing Interests

The authors declare that they have no competing interests.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Supplementary Tables

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Hendricks, A.E., Bochukova, E.G., Marenne, G. et al. Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity. Sci Rep 7, 4394 (2017). https://doi.org/10.1038/s41598-017-03054-8

Download citation

Received: 11 November 2016
Accepted: 10 April 2017
Published: 29 June 2017
DOI: https://doi.org/10.1038/s41598-017-03054-8

This article is cited by

Protein-truncating variants in BSN are associated with severe adult-onset obesity, type 2 diabetes and fatty liver disease
- Yajie Zhao
- Maria Chukanova
- John R. B. Perry
Nature Genetics (2024)
A rare human variant that disrupts GPR10 signalling causes weight gain in mice
- Fleur Talbot
- Claire H. Feetham
- I. Sadaf Farooqi
Nature Communications (2023)
The genetics of obesity: from discovery to biology
- Ruth J. F. Loos
- Giles S. H. Yeo
Nature Reviews Genetics (2022)
Human loss-of-function variants in the serotonin 2C receptor associated with obesity and maladaptive behavior
- Yang He
- Bas Brouwers
- I. Sadaf Farooqi
Nature Medicine (2022)
Human BDNF/TrkB variants impair hippocampal synaptogenesis and associate with neurobehavioural abnormalities
- Takuhiro Sonoyama
- Lukas K. J. Stadler
- I. Sadaf Farooqi
Scientific Reports (2020)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.